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Abstract Patients seeking medical care with erythema
migrans or flu-like symptoms after suspected or observed
tick bite in the southeast of Sweden and previously investi-
gated for Borrelia spp. and/or Anaplasma sp. were retro-
spectively examined for serological evidence of rickettsial
infection (Study 1). Twenty of 206 patients had IgG and/or
IgM antibodies to Rickettsia spp. equal to or higher than the
cut-off titre of 1:64. Seven of these 20 patients showed
seroconversion indicative of recent or current infection and
13 patients had titres compatible with past infection, of
which five patients were judged as probable infection. Of
19 patients with medical records, 11 were positive for Bor-
relia spp. as well, and for Anaplasma sp., one was judged as
positive. Five of the 19 patients had antibodies against all
three pathogens. Erythema migrans or rash was observed at
all combinations of seroreactivity, with symptoms in-
cluding fever, muscle pain, headache and respiratory
problems. The results were compared by screening an
additional 159 patients (Study 2) primarily sampled for
the analysis of Borrelia spp. or Mycoplasma pneumo-
niae. Sixteen of these patients were seroreactive for
Rickettsia spp., of which five were judged as recent or
current infection. Symptoms of arthritis, fever, cough
and rash were predominant. In 80 blood donors without
clinical symptoms, approximately 1 % were seroreactive
for Rickettsia spp., interpreted as past infection. The
study shows that both single and co-infections do occur,
which illustrate the complexity in the clinical picture
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and a need for further studies to fully understand how
these patients should best be treated.
Introduction
Tick-transmitted diseases are an emerging health problem in
temperate regions of the northern hemisphere. The hard tick
Ixodes ricinus is the main European vector for agents such
as Borrelia burgdorferi, Anaplasma phagocytophilum, tick-
borne encephalitis (TBE) virus and most of the species of
the spotted fever group of rickettsiae (SFG), of which at
least nine are recognised pathogens in humans in this part of
the world [1, 2].
In Sweden, predominantly Rickettsia helvetica, at a
variable prevalence of 1.7–17.3 % and in one case also
Rickettsia sibirica, have been detected in I. ricinus ticks
gathered from several parts of the country [3, 4]. Infections
with R. helvetica are usually recognised as a mild febrile
illness, but more severe symptoms such as perimyocarditis
and meningitis have been reported [5–10]. Another rickett-
sia, R. felis, whose main reservoir and vector is cat fleas
(Ctenocephalides felis), has, so far, not been reported in any
vector in Sweden, although it has been shown to cause
meningitis in two cases [11].
Ticks may be simultaneously co-infected with multiple
agents [3, 12]. However, co-infections in humans of multi-
ple tick-borne agents have rarely been studied [13]. The aim
of the present project was to examine the serological evi-
dence of rickettsial infections in a population naturally ex-
posed to ticks, the characteristic symptoms of the rickettsial
disease and to what extent rickettsial co-infections with
other tick-borne agents occur in Sweden.
The present report is a retrospective independent part of
a previous investigation (Study 1) examining serological
responses to several vector-borne agents in the same serum
material, in which the presence of antibodies to Borrelia
spp., Anaplasma sp. and TBE virus has been reported sep-
arately [14]. It includes also an additional serological exam-
ination (Study 2) of patients primarily sampled for possible
borreliosis as well as analysed for the presence of antibodies
to Mycoplasma spp.
Patients and methods
Patients and sera of Study 1
Sera were obtained from 206 patients seeking medical care
from May to December 2001 with flu-like symptoms or
erythema migrans (EM) after suspected or observed tick
bite in southeastern Sweden. The patients were between
the ages of 16 and 87 years, 110 (53 %) patients were
females and 96 (47 %) patients were males. Each patient
enrolled in the study was sampled for three sera (S1–S3);
enrolment day 0 (S1), sample 2 (S2) collected 6–8 weeks
after enrolment and a third sample (S3) 6 months after
enrolment. All sera were stored in the freezer for later
analysis. Two of these sera, S1 and S2, from all 206 patients
were analysed for rickettsial antibodies. Initially, sample
number 2 (S2) for all 206 serum samples were screened
for IgG antibodies to Rickettsia spp. Samples with a titre
equal to or higher than the cut-off titre of 1:64 were re-tested
for IgM (S2). The corresponding patient sample number 1
(S1) was, thereafter, examined in the same manner for IgG
and IgM antibodies against Rickettsia spp. S3 was not used
in this study. Data on symptoms and laboratory data were
obtained from medical records based on the initial exami-
nation and subsequent follow-up interview 6–8 weeks after
enrolment. Patient no. 1(Table 2) died during the study,
which is why data other than those reported are missing.
Prior to our study, the sera had been analysed for antibodies
against Borrelia spp., Anaplasma sp. and tick-borne enceph-
alitis (TBE) virus. Among these 206 patients, 186 patients
with Lyme borreliosis (LB) were found (174 with EM), 18
with confirmed and two with probable human granulocytic
anaplasmosis (HGA) and two cases of TBE [14].
Patients and sera of Study 2
A total of 112 patients who, regardless of indication, sub-
mitted samples for analysis of LB and 47 patients analysed
for Mycoplasma pneumoniae at Uppsala University Hospi-
tal during the period March–April 2012 were examined also
for the presence of rickettsial antibodies, in the same way as
in Study 1. Twenty-eight of 112 patients had serological
signs of actual or previous exposure to LB and 11 of 47
patients to M. pneumoniae.
As a control group, sera from 80 healthy blood




Antigen prepared from an aliquot of R. helvetica-infected
Vero cells was supplemented with 10 % yolk sac solution
and applied to microscope slide wells, dried, fixed in ace-
tone and incubated with serial dilutions of serum, as previ-
ously described [15]. As positive controls, a serum sample
from a patient with proven end-point IgG and IgM titres of
1:80 and 1:160, respectively, to R. helvetica and a serum
sample from a patient with proven infection with Rickettsia
conorii with end-point IgG titres of 1:160, provided by the
Swedish Institute for Infectious Disease Control (SMI),
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were used. Phosphate buffered saline was used as negative
control and all positive samples were re-tested with human
blood donor serum as negative control. IgG and IgM anti-
bodies were detected by specific polyclonal rabbit anti-
human fluorescein isothiocyanate-conjugated (FITC) γ
(IgG) and Mu-chain (IgM) conjugated antibodies (refs.:
F0202 and F0203; Dako, Glostrup, Denmark). The IgM
antibodies were examined after a pre-treatment procedure
with rheumatoid factor adsorbent (Immunkemi, Stockholm,
Sweden) to remove complex bound IgG antibodies. For
IgG, a titre ≥1:64 but <1:256 was considered a past infection
and >1:256 a recent or current infection, while <1:64 was
regarded as negative. For IgM, a titre <1:64 was considered
to be negative and >1:64 a recent or current infection. A
probable infection was defined as a 4-fold increase in IgG
antibody titre between S1 and S2 and with 1:128 as the
highest measured titre in S2.
Western blot (WB)
Sera at a dilution pf 1:400 from three of the IgG-positive
patients in Study 1 (nos. 6, 14 and 15) was tested for WB.
As the antigen, a 1,401 bp cloned DNA fragment of the
ompB gene of R. helvetica, amplified in the polymerase
chain reaction (PCR) assay, was ligated into a pET102/D-
TOPO vector and expressed in the BL21 component
Escherichia coli following the manufacturer’s instructions
(TOPO TA Cloning Kit for Sequencing, Invitrogen) as a
fusion protein of 61 kDa.
The 1,401 bp cloned DNA sequence of the ompB gene
corresponding to a 467 amino acid peptide of the native
protein (aa 761–1227) was amplified by primers chosen for
R. helvetica with the sequences (Rh-ompB-F) 5′CACA-
CAATCTGCCGATAATACCGG and (Rh-ompB-R) 5′
TACACCAGGTGCACCTCCA. The thermal cycle condi-
tions for PCR of the ompB gene of the rickettsiae have been
described previously [3]. The conventional PCR assays
were performed in a GeneAmp® PCR System 9700 (Ap-
plied Biosystems, Foster City, CA, USA). Amplified PCR
products were separated by electrophoresis on a 1 % agarose
gel stained with Gel Red™ (Biotium), illuminated by UV
light and compared with the DNA molecular weight marker
GeneRuler™ Express DNA ladder (Fermentas GmbH, St.
Leon-Rot, Germany). The purified peptide was dissolved in
Laemmli solution and transferred into nitrocellulose mem-
brane (Bio-Rad), blocked with 5 % non-fat dried milk and
overlaid with serum, incubated, washed and incubated with
horseradish peroxidase (HRP)-conjugated goat anti-
human IgG (Bio-Rad, Goat-anti-Rabbit, cat no. 172–
1050), as previously described [16]. A serum from
rabbit immunised with purified R. helvetica was used
as the positive control, and the secondary antibody
alone served as the negative control.
Methods used in previous analyses of Study 1
B. burgdorferi IgG and IgM were examined using a com-
mercial enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions for use and
interpretation (Genzyme Virotech GmbH, Rüsselsheim,
Germany). Positive or equivocal samples from ELISA were
further tested by WB (Genzyme Virotech GmbH, Rüssel-
sheim, Germany), using an Autoblot 36 (Genelabs Diagnos-
tics, Irvine, CA, USA). The patients were considered to be
positive based on seroconversion, a significant rise in IgG
titre and/or appearance of new significant bands in the WB
banding pattern between S1 and S2. IgG antibodies (S1 and
S2) to A. phagocytophilum were detected using a commer-
cial kit (Focus Technologies, Cypress, CA, USA). A titre
>1:80 was considered to be positive and laboratory evidence
of infection was based on seroconversion or a >4-fold rise in
titre between S1 and S2. A probable infection was defined
as a permanently high IgG antibody titre of ≥1:640 or at
least a 4-fold decrease in IgG antibody titre during the
investigation period. Infection with TBE virus was based
on positive IgM screen (S1) [Immunozym FSME (Frühsom-
mer-Meningoenzephalitis) IgM or Progen Biotechnik
GmbH, Germany] and confirmed by the rapid fluorescent
focus inhibition test (RFFIT) [14, 17].
Methods used in previous analyses of Study 2
All sera were analysed for IgG and IgM antibodies against
Borrelia spp. using the Euroimmun’s ELISA kit [Euroim-
mun AG (Aktiengesellschaft), Lübeck, Germany], accord-
ing to the manufacturer’s instructions.
Results
Study 1
The serological results and details from the medical records
on each patient are summarised in Tables 1 and 2. Of all
patients analysed, 20/206 (9.7 %) had IgG and/or IgM anti-
bodies to Rickettsia spp. equal to or higher than the cut-off
titre of 1:64 (Table 1). All negative controls were negative.
All but one patient had available medical records from the
time of disease, and their data are summarised in Table 2.
Seven of the patients were males and 13 were females. The
median age was 54 years, range 20–74 years. Seven of the
seroreactive patients (nos. 1, 6, 7, 9, 14, 15 and 19) showed
seroconversion or significant rise of titre, indicating recent
infection or current infection, and 13 patients had titres
compatible with past infection, of which five patients (nos.
5, 8, 13, 17 and 18) were judged as probable infection.
Eleven of the 19 Rickettsia spp. seroreactive patients were
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positive also for Borrelia spp. Six of the 19 were seroreac-
tive for Anaplasma sp., of which five were serologically
judged as having a probable infection and one was judged as
positive. Five patients were seroreactive for all three agents
(Table 2). None of the patients that were seroreactive for
Rickettsia spp. were co-infected with TBE. Seven of the 19
patients had detectable antibodies only for Rickettsia spp.,
two of which had titres indicating recent infection, three
compatible with past infection and two a probable infection.
EM and/or rash for a period of 0–7 days were observed at all
combinations of seroreactivity (Table 2). A total of 15
patients presented EM (between 5 and 15 cm in diameter).
Nine of these 15 were co-infected with Borrelia spp. and/or
Anaplasma sp., and six patients presenting EM had anti-
bodies only against Rickettsia spp. The corresponding fig-
ures for the rash were nine Rickettsia spp.-reactive, of which
six were co-infected (Table 2). Seventeen of the 19 Rickett-
sia spp.-reactive patients were tick-bitten 1–4 weeks earlier,
two had suspected bites, five reported fever (>37.5 and
<39 °C) lasting less than 1 week and 4 of 5 also experienced
chills for a period of 0–3 days. Eight experienced headache
lasting between 0 and 7 days. Five of 19 patients had muscle
pain. Seven of 19 had respiratory symptoms, usually cough.
All patients showed normal values for haemoglobin, white
blood cell count, platelet cell count, alanine and aspartate
aminotransferase, and lactate dehydrogenase in both serum
S1 and S2. Three of the 19 patients were treated with
doxycycline 100 mg once a day, the others with phenoxi-
methyl penicillin. All patients except one (no. 7) were cured
at follow-up after 2 months. Patient no. 7 showed persistent
skin problems. WB for patient nos. 6, 14 and 15 showed a
specific response to the mass-specific protein antigen in the
60-kDa region for IgG (Fig. 1).
Study 2
The serological results and the symptoms of the patients are
summarised in Table 3. Sixteen patients were seroreactive
for Rickettsia spp. Eleven of the 16 patients were primarily
analysed for Borrelia spp., of which four (patients C, D, I
and L in Table 3) were found to be seroreactive for Rickett-
sia spp., consistent with recent or current infection, and five
of the 16 patients were primarily analysed for M. pneumo-
niae, of which one (patient P in Table 3) showed serological
evidence of recent or current infection. The symptoms for
each patient are shown in Table 3. The referring physicians
had reported arthritis, rash, abdominal discomfort, muscle
weakness, myalgia and prolonged cough. Cough and arthri-
tis (including joint swelling, stiffness and pain) were pre-
dominant symptoms independent of the primary indication
for sampling. In the control group of blood donors, all
without clinical symptoms, one of the 80 patients had IgG
1:64 and IgM 1:64–1:128, respectively, interpreted as a
previous exposure. Three of the 80 patients had only IgM
between 1:64–1:128 and was non-reactive for IgG, proba-
bly as a result of non-specific reactivity or previous expo-
sure. The re-testing of all seroreactive showed equivalent
results.
Discussion
This report presents the serological evidence of recent or
probable rickettsial infection, in most cases, probable co-
infection, in almost 6 % of patients from a prospective,
clinical investigation (Study 1), where patients were
recruited on the basis of EM and/or general signs of infec-
tion (fever, headache, muscle pain) following known or
probable tick bite (Table 1). Three patients had IgG anti-
bodies at the first visit, probably due to a past infection, and
another 17 patients showed seroconversion or a 4-fold rise
in IgG titre at the second visit, of which seven had a recent
or current infection and ten a past infection, of which five
were judged as probable infection. IgG and IgM antibodies
normally appear 3–10 days after disease onset and peak after
3–4 weeks. Treatment within 2–5 days of disease onset may
also inhibit antibody production. Seventeen of the 20
Table 1 Antibody titres of serums 1 (S1) and 2(S2) for the 20 Rick-
ettsia spp.-seroreactive patients in Study 1
Patient no. S1 S2
IgG IgM IgG IgM
1 <64 128 512 64
2 <64 <64 64 <64
3 128 128 64 <64
4 64 64 64 <64
5 <64 128 128 64
6 <64 <64 1,024 64
7 <64 64 256 128
8 <64 64 128 <64
9 <64 128 256 64
10 <64 128 64 <64
11 <64 256 <64 64
12 <64 256 64 64
13 <64 128 128 64
14 <64 128 512 <64
15 <64 128 512 <64
16 <64 128 64 <64
17 <64 128 128 64
18 64 <64 128 64
19 <64 128 512 <64
20 <64 128 64 <64
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patients had only IgM titre at the first visit, while 10/20 were
seronegative for IgM at the second visit, which shows the
importance of paired sera for the analysis of both IgG and
IgM antibodies to establish a reliable serological diagnosis.
The specificity of the serological response showing the
presence of IgG antibodies to Rickettsia-specific protein
was demonstrated by WB analysis in three of the seroreac-
tive samples (S2) (Fig. 1).
The study also shows that Rickettsia spp. infection
occurs either as a single infection or as a co-infection in
patients with EM or serological evidence of Borrelia spp. or
Anaplasma sp. infection. Of the 206 patients in the study,
174 were recruited on the basis of EM and 32 because of flu-
like symptoms in combination with a preceding tick bite. All
patients who were seroreactive for Rickettsia spp. in paired
sera presented different disease symptoms comparable to
those of LB (Table 2). The observed symptoms were similar
and gave no guidance in relation to the causative agent. The
variability of the clinical picture in LB has been highlighted
in a recent report showing that asymptomatic B. burgdorferi
infections, documented by seroconversion, were found more
often than symptomatic infections in individuals bitten by a
B. burgdorferi-infected tick [18]. No corresponding study
has been carried out regarding Rickettsia, but in the present
study, all patients with proven rickettsial antibodies
Table 2 Clinical symptoms, number of tick bites, treatment and results of serology for Borrelia spp. and Anaplasma sp. for the Rickettsia spp.-
















1 76 M ND ND ND ND ND ND ND ND ND pc
2 70 F Y N Y N N N Y Neg Neg pc
3 59 F Y N Y N Y N Y Neg Neg pc
4 59 M S N N N Y N Y Neg Neg pc
5 57 F Y N N N N Y Y Neg Neg pc
6 57 F Y Y Y N Y Y Y Neg Neg pc
7 46 M Y (>1) Y Y Y N Y N Neg Neg pc
8 20 F Y N N N N N Y Neg Neg pc
9 74 M Y N N Y Y N N Pos Pos doxy
10 70 F Y N N N Y N Y Pos Neg pc
11 68 F S N N N N N Y Neg P pc
12 61 F Y N Y N Y N Y Pos P pc
13 57 F Y N Y N N Y Y Pos Neg pc
14 56 M Y N N N Y N Y Pos Neg pc
15 55 F Y N N N N N Y Pos Neg doxy
16 54 F Y N N N Y Y Y Pos P pc
17 52 M Y (>1) Y Y Y N N Y Pos P pc
18 51 M Y (>1) Y Y Y N Y N Pos P doxy
19 43 F S N N N Y N Y Pos Neg pc
20 26 F Y (>1) Y N Y N Y N Pos Neg pc
ND no data available; Y yes; N no; S suspected; P probable; EM erythema migrans; doxy doxycycline, pc penicillin
Fig. 1 Western blot (WB) analysis of IgG antibodies against an antigenic
peptide (ompB) of Rickettsia helvetica. Lanes A, B and C demonstrate the
specific reactions for each serumsample (S2) forpatientnos. 6,14and15 in
Study1 against the protein in the60-kDa region.LaneD shows the specific
reaction between the antigenic peptide and polyclonal rabbit anti-serum
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presented varying degrees of symptoms. However, the
symptoms of Rickettsia spp. or B. burgdorferi infection
are, in both cases, quite general and do not allow us to
distinguish between the agents.
EM is typically regarded as a clinical sign consistent
with LB [19]. Fifteen of the 19 Rickettsia spp.-seroreactive
patients showed EM, of whom eight were serologically
positive also for Borrelia spp. EM occurred also in six of
the seven (6/206, 2.9 %) patients who were seroreactive
only for Rickettsia spp., which may indicate that either the
Rickettsia infection was causative or that Lyme infection did
not produce antibody development. There are only a few
previous reports in which EM or erythema resembling EM
has been associated with rickettsial infection [20, 21]. Fur-
ther serological examination including several agents in
prospective clinical cases may provide more guidance as
to the causative agent. Skin biopsy for PCR and/or immu-
nohistochemistry and the detection of Rickettsia spp., Bor-
relia spp. and/or Anaplasma sp. organisms are also likely to
be of value in clarifying the cause. Because several tick-
borne agents give similar symptoms and, as the present
study indicates, may occur as co-infections or separately,
the task of providing a correct diagnosis is complex. In
patients exposed to ticks presenting with unspecific symp-
toms, there is reason to consider the choice of antibiotics if
other infectious agents are not excluded [14]. If EM is the
only found symptom and causes other than LB can be
excluded, it is likely that phenoxymethylpenicillin is suffi-
cient as the drug of choice. Thus, serological testing is
important for a full clinical assessment of underlying causes.
Study 2 gives a similar picture for 16 seroreactive
patients with symptoms involving the skin, joints (culture-
negative arthritis), headache and cough. The reason for the
cough symptom requires further study, but it is known that
rickettsiosis gives pulmonary vasculitis, which could be a
possible explanation.
Screening for Rickettsia spp. from different localities in
Sweden, using PCR, has demonstrated a mean infection
prevalence of 1.5–17.3 % for R. helvetica in I. ricinus ticks,
including all stages, proving that Sweden is an endemic area
for this agent and that the risk of infection is consistent with
the tick’s distribution [4].
Previous smaller serosurveys in Sweden have shown
IgG antibodies to Rickettsia spp. in the serum of up to
4.4 % of tick-exposed subjects, compared to 0.6 % in
healthy blood donors [15]. In a prospective study of Swed-
ish recruits who trained in the coastal areas, 8.9 % showed
seroconversion compared to the proportion of 9.2 % found
to be seroreactive in France in a group of forestry workers,
and in a study from Laos, 2.9 % of adults admitted to
hospital because of fever showed seroconversion to R. hel-
vetica [5, 6, 22, 23].
The current more extensive study demonstrates both
seroconversion and significant rise of titres for Rickettsia
spp. in single-infected individuals as well as in those
patients co-infected with other tick-borne agents known to
present similar clinical symptoms. The complexity of the
clinical picture needs to be considered when diagnosing the
causative agent and selecting appropriate treatment. It also
demonstrates a need for further studies.
Table 3 Antibody titres and
symptoms for patients in Study 2
M.p. Mycoplasma pneumoniae;
ND no data available; EM ery-
thema migrans
Patient S1 Borrelia serology M.p. serology Symptoms
IgG IgM
A 128 128 Neg ND EM
B 128 64 Neg ND Arthritis
C 256 1,024 Pos (IgG) ND EM
D 256 <64 Neg ND Abdominal
E 64 <64 Pos (IgG/M) ND Arthritis
F <64 64 Pos (IgM) ND EM
H <64 128 Neg ND Cough
I 512 512 Neg ND Cough, arthritis
J 32 256 Pos (IgG) ND Myalgia/tendinitis
K 64 128 Pos (IgG) ND Cough
L 256 <64 Neg ND Neuropathia
P 2,048 256 ND Neg Fever, cough
Q 128 64 ND Neg Fever, cough
R <64 256 ND Neg Cough
S 64 64 ND Pos (IgG) Cough
T 64 128 ND Neg Abdominal
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